[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitively-normal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitively-normal":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100525894","brain-vascular-and-neural-function-linked-to-balance-across-the-adult-lifespan-100525894",false,"NCT06127667","Brain Vascular and Neural Function Linked to Balance Across the Adult Lifespan","Inclusion Criteria:\n\n* Age within the following 3 group age ranges, 21-30yo; middle-aged: 40-55yo; older: 65-95yo adults\n* the absence of major orthopedic disability\n* cognitively normal (MoCA score ≥ 26\u002F30 in older adult group)\n* vision that is 20\u002F40 or better with or without corrective lenses, (5) the ability to consent and communicate with researchers\n* English speaking\n* ability to stand for 3 minutes and walk 10 meters with or without an assistive device and without the assistance of another person.\n\nExclusion Criteria:\n\n* insulin-dependent diabetes\n* peripheral neuropathy\n* myocardial infarction or symptoms of coronary artery disease within 2 years\n* congestive heart failure or class IV heart failure\n* any significant sensory impairment affecting balance or cognition; visual, vestibular, or auditory impairments.",true,"ALL","21 Years","95 Years",{"count":20,"type":21},102,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a single-arm, two-visit, non-randomized, cross sectional study identified as an intervention due to the use of a single bout of aerobic exercise to assess cerebrovascular function under the NIH rules. This study is not masked and its primary purpose is to develop a basic science understanding of the relationship between cerebrovascular health and balance control with aging. This study will involve 102 individuals classified as younger adults, middle-aged adults, and older adults who are neurotypical and cognitively normal. The primary outcome from a clinical trials perspective will be cerebrovascular response to a bout of aerobic exercise (i.e. change in cerebral blood flow with the performance of aerobic exercise on a recumbent stepper exercise machine). Non-interventional outcomes will be EEG measures of cortical activity and biomechanical kinetic and kinematic data recorded during standing balance reactions, as well as biological blood samples for genomic analysis.",[27,28],"Neurotypical","Cognitively Normal","RECRUITING","2026-03-26",{"date":32,"type":33},"2026-03-27","ACTUAL",{"date":35,"type":33},"2024-10-15",{"date":37,"type":21},"2028-07-01",{"name":39,"class":40},"University of Minnesota","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":15,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100474330","phase-3-pet-imaging-tau-accumulation-in-ftld-and-atypical-alzheimers-using-18f-pi-2620-100474330","NCT05456503","PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620","Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Disease Using the PET Ligand [18F]-PI-2620","Inclusion Criteria: participants must fulfill all of the criteria for one of the following groups.\n\n1\\. Group 1: cognitively and neurologically normal subjects (CN, n=25)\n\n1. Male or female ≥ 18 years of age currently enrolled in UNICORN (IRB #842873)\n2. Cognitively and neurologically normal according to one of the following criteria:\n\n   i. Mini-Mental Status Exam (MMSE; Folstein et al., 1975) score \\> 27, OR ii. Montreal Cognitive Assessment (MoCA; Carson et al., 2017; Nasreddine et al., 2005) score \\> 25, OR iii. Global Clinical Dementia Rating of 0, OR iv. Evaluation by a trained clinician\n3. Not clinically depressed, according to one of the following criteria:\n\n   i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician\n4. No history of early-onset neurodegenerative disease in biological siblings or parents, based on the investigators' assessment of the participant's self-reported history.\n\n2\\. Group 2: non-amnestic Alzheimer's disease (naAD, n=15)\n\n1. Male or female ≥ 18 years of age currently enrolled in UNICORN (IRB #842873)\n2. Clinically diagnosed by a trained clinician as having a non-amnestic syndrome attributed to likely AD pathology, including but not limited to logopenic-variant primary progressive aphasia (lvPPA), posterior cortical atrophy (PCA), behavioral\u002Fdysexecutive AD (bvAD), corticobasal syndrome due to AD (CBS-AD), non-amnestic mild cognitive impairment (naMCI), or non-amnestic AD (naAD).\n3. Not clinically depressed, according to one of the following criteria:\n\n   i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician\n4. Have a study partner and LAR (if applicable) who can participate as outlined in the protocol. Please see page 15 for further clarification.\n\n3\\. Group 3: FTLD likely due to tau (FTLD-tau, n=25)\n\n1. Male or female ≥ 18 years of age currently enrolled in UNICORN (IRB #842873)\n2. Clinically diagnosed by a trained clinician as having a neurodegenerative syndrome likely due to tau , including but not limited to progressive supranuclear palsy (PSP), non-fluent agrammatic primary progressive aphasia (naPPA), corticobasal syndrome (CBS), or behavioral-variant frontotemporal dementia (bvFTD).\n3. Not clinically depressed, according to one of the following criteria:\n\n   i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician\n4. Have a study partner and LAR (if applicable) who can participate as outlined in the protocol. Please see page 15 for further clarification.\n\n4\\. Group 4: FTLD likely due to TDP-43 (FTLD-TDP, n=12)\n\n1. Male or female ≥ 18 years of age currently enrolled in UNICORN (IRB #842873)\n2. Clinically diagnosed by a trained clinician as having a dementia syndrome associated with likely TDP-43 pathology, including but not limited to amyotrophic lateral sclerosis with frontotemporal dementia (ALS-FTD) or semantic-variant primary progressive aphasia (svPPA).\n3. Not clinically depressed, according to one of the following criteria:\n\n   i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician\n4. Have a study partner and LAR (if applicable) who can participate as outlined in the protocol. Please see page 15 for further clarification.\n5. Group 5: having a known genetic mutation associated with FTLD-tau (genetic FTLD-tau, n=12)\n\n1\\. Male or female ≥ 18 years of age 2. Currently enrolled in UNICORN (IRB #842873) with a genetic test result indicating a mutation in the MAPT gene.\n\n3\\. Clinically diagnosed by a trained clinician as having an appropriate neurodegenerative condition OR confirmed as an asymptomatic mutation carrier.\n\n4\\. Not clinically depressed, according to one of the following criteria: i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician 5. Have a study partner and LAR (if applicable) who can participate as outlined in the protocol. Please see page 15 for further clarification.\n\n6\\. Group 6: having a known genetic mutation associated with FTLD-TDP (genetic FTLD-TDP, n=3)\n\n1. Male or female ≥ 18 years of age\n2. Currently enrolled in UNICORN (IRB #842873) with a genetic test result indicating a mutation in the GRN gene or in open reading frame 72 of chromosome 9 (C9orf72).\n3. Clinically diagnosed by a trained clinician as having an appropriate neurodegenerative condition OR confirmed as an asymptomatic mutation carrier.\n4. Not clinically depressed, according to one of the following criteria:\n\n   i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician\n5. Have a study partner and LAR (if applicable) who can participate as outlined in the protocol. Please see page 15 for further clarification.\n\n7\\. Group 7: amnestic Alzheimer's disease (naAD, n=15)\n\n1. Male or female ≥ 18 years of age currently enrolled in UNICORN (IRB #842873)\n2. Clinically diagnosed by a trained clinician as having amnestic mild cognitive impairment (MCI) or amnestic Alzheimer's disease (aAD).\n3. Not clinically depressed, according to one of the following criteria:\n\n   i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician\n4. Have a study partner and LAR (if applicable) who can participate as outlined in the protocol. Please see page 15 for further clarification.\n\nExclusion Criteria for all groups: Participants will be excluded from enrollment if they meet any of the following criteria.\n\n1. The participant has any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the participant's safety or successful participation in the study.\n2. The investigators of UNICORN (IRB #842873) have determined the participant has evidence of structural abnormalities such as major stroke or mass on MRI scan within \\\u003C 6 months prior to enrollment that is likely to interfere with analysis of the PET scan.\n3. The participant is unable to tolerate or have a contraindication to imaging procedures in the opinion of an investigator.\n4. Females who are pregnant or breast feeding at the time of the baseline PET\u002FCT scan will not be eligible for this study. A urine pregnancy test will be performed in women of child-bearing potential at screening and within 24 hours of any scheduled PET\u002FCT.\n5. The participant has a history of significant past or ongoing alcohol abuse or substance abuse, or dependence based on medical record review or self-reported (may be excluded at the discretion of the investigator.)\n6. The participant is enrolled in a clinical trial for a disease-modifying treatment that targets the molecular pathology underlying their neurodegenerative disease.","18 Years",{"count":51,"type":21},72,[53],"PHASE3","The investigators will compare \\[18F\\]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.",[56,57,28],"Frontotemporal Lobar Degeneration","Alzheimer Disease","2025-11-03",{"date":60,"type":33},"2025-11-04",{"date":62,"type":33},"2022-09-19",{"date":64,"type":21},"2028-08",{"name":66,"class":40},"University of Pennsylvania"]